Login
EN
Phones:
+7 (495) 482-41-18
+7 (495) 482-43-29

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

A.V. Shchulkin

Ryazan State Medical University, Ryazan, Russia

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(12–2): 87–93

A modern concept of antihypoxic and antioxidant effects of mexidol

Authors:

A.V. Shchulkin

Ryazan State Medical University, Ryazan, Russia

DOI: 10.17116/jnevro201811812287

Read: 15142 times

Download PDF
Download PDF (RU)
Contact the author
Table of contents

Open to cite this article

Shchulkin AV. A modern concept of antihypoxic and antioxidant effects of mexidol. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(12‑2):87‑93. (In Russ., In Engl.).
https://doi.org/10.17116/jnevro201811812287

Close metadata
Recommended articles:
Improving the quality of life and the possibility of pathogenetic therapy in adult patients with cere­bral palsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):75-84
Cognitive dysfunction in children with nervous system diseases: modern approaches to diagnosis and treatment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10-2):69-79
Brain aging: mole­cular targets of gero­protection and prevention stra­tegies. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11):132-139
Multimodal antioxidant therapy in ischemic stroke: from MIR trial to bedside. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(12-2):64-71
Dyna­mics of cognitive functions and vege­tative status in patients with arte­rial hype­rtension of working age on the background of Mexi­dol treatment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(12):100-105
The effect of neuroprotectors on the level of BDNF, tumor necrosis factor alpha and apoptosis markers, and in acute cere­brovascular acci­dents. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(2):123-129
Evaluation of the neuroprotective acti­vity of Mexi­dol in a model of hemo­rrhagic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(3-2):40-45
Drug-drug inte­ractions with Mexi­dol in patients with ischemic stroke: Analysis of data from randomized clinical trials. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(3):141-154
The cere­broprotective effe­cts of Mexi­dol in patients with hype­rtension. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(4):113-118
Systemic inflammation in spastic forms of cere­bral palsy: pathogenetic role and modu­lation possibilities using Mexi­dol in motor reha­bilitation of pediatric patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(5):74-82

The review article presents a modern concept of the mechanism of antioxidant and antihypoxic action of the original drug mexidol (2-ethyl-6-methyl-3-hydroxypyridine succinate). The direct antioxidant activity of mexidol has been described, which consists in the ability of the drug to inactivate free radicals and increase the activity of the antioxidant enzymes glutathione peroxidase and superoxide dismutase in vitro. The results of the indirect antioxidant activity of mexidol, manifested in the increased expression under the ischemia of the transcription factor Nrf2, responsible for the cell resistance to oxidative stress are presented. The antihypoxic action of mexidol due to the presence of succinic acid in its molecule, which on the one hand supports the work of the Krebs cycle succinate oxidase under oxygen deficiency conditions, and on the other hand, binds to its specific receptors (GPR91), and starts a cascade of biochemical reactions that increases the body’s resistance to lack of oxygen is discussed. The results of preclinical and clinical studies confirming the antioxidant and antihypoxic effects of mexidol are summarized.

Keywords:

mexidol
ethylmethylhydroxypyridine succinate
antioxidant
antihypoxant

Authors:

A.V. Shchulkin

Ryazan State Medical University, Ryazan, Russia

List of references:

  1. Voronina TA. Mexidol: main neuropsychotropic effects and mechanisms of action. Farmateka. 2009;6:28-31. (In Russ.)
  2. Voronina TA. Mexidol: the spectrum of pharmacological effects. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;112(12):86-90. Accessed October 16, 2018. (In Russ.) https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova/2012/12/031997-729820121215
  3. Schulkin AV. Mexidol: modern aspects of the pharmacokinetics and pharmacodynamics. Farmateka. 2016;4:65-71. (In Russ.)
  4. Okunevich IV, Sapronov NS. Antioksidanty: effektivnost’ prirodnykh i sinteticheskikh soedinenii v kompleksnoi terapii serdechno-sosudistykh zabolevanii. Obzory po klinicheskoi farmakologii i lekarstvennoi terapii. 2004;3(3):2-17. Accessed October 16, 2018. (In Russ.) https://elibrary.ru/item.asp?id=9288234
  5. Vladimirov YuA. Svobodnye radikaly i antioksidanty. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk. 1998;7:43-51. (In Russ.)
  6. Zarubina IV, Shabanov PD. Molekulyarnaya farmakologiya antigipoksantov. SPb.: OOO «Izd-vo N-L»; 2004. (In Russ.)
  7. Zaitsev VG, Ostrovskii OS, Zakrevskii VI. Glassification of the direct-acting antioxidants based on a relationship between chemical structure and target. Eksperimental’naya i klinicheskaya farmakologiya. 2003;66(4):66-70. Accessed October 16, 2018. (In Russ.) http://ekf.folium.ru/index.php/ekf/article/view/1430/1381
  8. Shchulkin AV. Effect of mexidol on the development of the phenomenon of the neuronal excitotoxicity in vitro. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;112(2):35-39. Accessed October 16, 2018. (In Russ.) https://www.mediasphera.ru/issues/zhurnal nevrologiiipsikhiatriiimsskorsakova/2012/2/031997-7298201226
  9. Kosolapov VA, Spasov AA, Anisimova V. A Study of antiradical activity of new compounds by chemiluminescence. Biomeditsinskaya Khimiya. 2005;51(3):287-294. Accessed October 16, 2018. (In Russ.) http://pbmc.ibmc.msk.ru/index.php/ru/article/PBMC-2005-51-3-287-ru
  10. Teselkin YuO, Davydov BV. Ingibirovanie meksidolom peroksidnogo okisleniya lipoproteinov syvorotki krovi. Byulleten’ Eksperimental’noi Biologii i Meditsiny. 2006;1:139-143. (In Russ.)
  11. Solov’ev NA, Yasnetsov VV. Eksperimental’no-klinicheskoe issledovanie deistviya meksidola pri nekotoroi patologii. Vyyasnenie vozmozhnoi lokalizatsii i mekhanizma deistviya. Byulleten’ Eksperimental’noi Biologii i Meditsiny. 2006;1:230-241. (In Russ.)
  12. Kiselyova OS, Farkhutdinov RR. Medication effects on active oxygen generation and lipid peroxidation processes in the treatment of ischemic strokes in model systems. Medicinskij Vestnik Bashkortostana. 2011;6(3):124-126. Accessed October 16, 2018. (In Russ.) https://elibrary.ru/item.asp?id=17047870
  13. Patologiya: Uchebnik. V 2 t. Pod red. Chereshneva V.A., Davydova V.V. T. 1. M.: Izd-vo «GEOTAR-Media»; 2009. (In Russ.)
  14. Vinogradov VM, Uryupov OYu. Gipoksiya kak farmakologicheskaya problema. Farmakologiya i Toksikologiya. 1985;48(4):9-2. (In Russ.)
  15. Lukyanova LD. Mithochondria signaling in adaptation to hypoxia. Physiological Magazine. 2013;59(6):141-154. Accessed October 16, 2018. (In Russ.) http://www.irbisnbuv.gov.ua/cgibin/irbis_nbuv/cgiirbis_64.exe?I21DBN=LINK&P21DBN=UJRN&Z21ID=&S21REF=10&S21CNR=20&S21STN=1&S21FMT=ASP_meta&C21COM=S&2_S21P03=FILA=&2_S21STR=Fiziol_2013_59_6_20
  16. Rumyantseva SA, Stupin VA, Afanas’ev VV, Bolevich SB, Fedin AI, Silina EV, Khokonov MA, Goluzova YuN. Vtoroi shans (sovremennye predstavleniya ob energokorrektsii). M.: MIG «Meditsinskaya kniga»; 2010. (In Russ.)
  17. Pearl JM, Hiramoto J, Laks H, Drinkwater DC, Chang PA. Fumarate-enriched blood cardioplegia results in complete functional recovery of immature myocardium. Annals Thoracic Surgery. 1993;57:1636-1641.
  18. Maevskii EI, Grishina EV, Rozenfel’d AS, Zyakun AM, Vereshchagina IM, Kondrashova MN. Anaerobnoe obrazovanie suktsinata i oblegchenie ego okisleniya vozmozhnye mekhanizmy adaptatsii kletki k kislorodnomu golodaniyu. Medline. 2000;1(3):32-36. Accessed October 16, 2018. (In Russ.) http://www.medline.ru/public/art/tom1/art3.phtml
  19. Okovity SV, Rad’ko SV, Shustov EB. Succinate Receptors (SUCNR1) as a Potential Target for Pharmacotherapy. Pharmaceutical Chemistry Journal. 2015;49(9):573-577. Accessed October 16, 2018. (In Russ.) http://chem.folium.ru/index.php/chem/article/view/3095
  20. Pogorely VI, Arlt AV, Gaevyi MD, Gatsura VV, Smirnov LD. The antiischemic effects of 3-oxypyridine derivatives in cerebrovascular pathology. Eksperimental’naya i Klinicheskaya Farmakologiya. 1999;62(5):15-17. (In Russ.)
  21. Povarova OV, Garibova TL, Kalenikova EI, Galaeva IP, Kraineva VA, Medvedev OS, Voronina TA. The effect of phenyl-tert-butylnitrone, mexidol, and nooglutyl on the ischemic cerebral affection zone and memory of rats upon medial cerebral artery occlusion. Eksperimental’naya i Klinicheskaya Farmakologiya. 1999;62(5):15-17. Accessed October 16, 2018. (In Russ.) http://ekf.folium.ru/index.php/ekf/article/view/1231/1184
  22. Kraineva VA. Osobennosti i mekhanizm neiroprotektivnogo deistviya meksidola pri gemorragicheskom insul’te v eksperimente. Insul’t. 2006;17:71-76. (In Russ.)
  23. Makarova LM. Neiroprotektornoe deistvie preparata Meksidol pri total’noi ishemii mozga (k voprosu o tselesoobraznosti primeneniya dannogo preparata pri gravitatsionnykh peregruzkakh). Byulleten’ eksperimental’noi biologii i meditsiny. 2006;S1:48-54. (In Russ.)
  24. Nechipurenko NI, Vasilevskaya LA, Griboedova TV, Shcherbina NYu, Musienko YuI. Effektivnost’ preparata Meksidol pri eksperimental’noi ishemii golovnogo mozga. Byulleten’ eksperimental’noi biologii i meditsiny. 2006;1:224-229. (In Russ.)
  25. Korshunova AB, Prosvirkina IA. Perspektivy primeneniya meksidola pri ishemicheskikh i metabolicheskikh narusheniyakh. Byulleten’ eksperimental’noi biologii i meditsiny. 2012;1:257-263. (In Russ.)
  26. Yakusheva EN, Mylnikov PYu, Chernykh IV, Shchulkin AV. Mexidol effect on the factor induced by hypoxia HIF-1α expression in the rat cerebral cortex in ischemia. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117(10):87-91. Accessed October 16, 2018. (In Russ.) https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova/2017/10/downloads/ru/1199772982017101087
  27. Yakusheva EN, Mylnikov PYu, Chernykh IV, Shchulkin AV. An effect of mexidol on the expression of the transcription factor Nrf2 in the rat cerebral cortex in ischemia. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2018;118(5):64-68. Accessed October 16, 2018. (In Russ.) https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova/2018/5/1199772982018051064
  28. Smirnova IN, Fedorova TN, Tanashyan MM, Suslina ZA. Klinicheskaya effektivnost’ i antioksidantnaya aktivnost’ Meksidola pri khronicheskikh tserebrovaskulyarnykh zabolevaniyakh. Atmosfera. Nervnye Bolezni. 2006;1:33-36. Accessed October 16, 2018. (In Russ.) https://elibrary.ru/item.asp?id=17291889
  29. Abramenko YuV. The assessment of the clinical efficacy, vasoactive and metabolic effects of mexidol in elderly patients with discirculatory encephalopathy. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2011;111(11):35-41. Accessed October 16, 2018. (In Russ.) https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova/2011/11/downloads/ru/031997-72982011116
  30. Duma SN. Possibilities of antioxidant therapy for asthenia and cognitive deficit in elderly patients with chronic brain ischemia. Terapevticheskij Arhiv. 2013;85(12):100-105. Accessed October 16, 2018. (In Russ.) https://elibrary.ru/item.asp?id=21085290
  31. Skvortsova VI, Stakhovskaya LV, Nartsissov YaR, Bodykhov MK, Kichuk IV, Gudkova YuV, Soldatenkova TD, Kondrashova TT, Kalinina EV, Novichkova MD, Kerbikov OB. The randomized double-blind placebo-controlled study of efficacy and safety of mexidol in the complex therapy of ischemic stroke in the acute period]. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2006;106:18:47-54. (In Russ.)
  32. Lutsky MA. An analysis of mexidol efficacy in the complex treatment of patients with ischemic stroke. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2010;110(4-2):57-59. Accessed October 16, 2018. (In Russ.) https://medi.ru/info/2922
  33. Odinak MM, Yanishevskiĭ SN, Tsygan NV, Golokhvastov SYu, Vozniuk IA, Trufanov AG. The use of succinates for the correction of metabolic disorders in the penumbra in patients with stroke. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2013;113(12-2):55-60. Accessed October 16, 2018. (In Russ.) https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova-2/2013/12/downloads/ru/031997-729820131239
Contact the author
Email
Message

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
E-mail
Password
Forgot Password?

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.